Foghorn Therapeutics Inc. (FHTX)
NASDAQ: FHTX · Real-Time Price · USD
4.545
-0.125 (-2.68%)
Sep 10, 2026, 10:46 AM EDT - Market open
Foghorn Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 36.74 | 30.91 | 22.6 | 34.16 | 19.23 | 1.32 | |
Revenue Growth | 51.98% | 36.75% | -33.83% | 77.63% | 1357.77% | 206.74% |
Cost of Revenue | 78.83 | 85.47 | 94.53 | 109.69 | 105.62 | 80.33 |
Gross Profit | -42.09 | -54.56 | -71.93 | -75.53 | -86.39 | -79.01 |
Selling, General & Admin | 26.38 | 27.55 | 28.36 | 32.37 | 30.75 | 21.73 |
Operating Expenses | 26.38 | 27.55 | 28.36 | 32.37 | 30.75 | 21.73 |
Operating Income | -68.48 | -82.11 | -100.29 | -107.91 | -117.14 | -100.73 |
Interest Expense | - | - | - | - | - | -1.91 |
Interest & Investment Income | 7.1 | 8.75 | 11.9 | 10.88 | 5.68 | 0.06 |
Other Non Operating Income (Expenses) | 1.08 | 3.36 | 4.16 | 2.83 | 2.58 | 2.49 |
EBT Excluding Unusual Items | -60.3 | -70 | -84.22 | -94.2 | -108.88 | -100.09 |
Asset Writedown | -5.91 | -5.91 | -2.4 | - | - | - |
Other Unusual Items | 1.63 | 1.63 | - | - | - | -1.23 |
Pretax Income | -64.58 | -74.28 | -86.62 | -94.2 | -108.88 | -101.32 |
Income Tax Expense | - | - | - | 4.23 | - | - |
Net Income | -64.58 | -74.28 | -86.62 | -98.43 | -108.88 | -101.32 |
Net Income to Common | -64.58 | -74.28 | -86.62 | -98.43 | -108.88 | -101.32 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 67 | 63 | 55 | 42 | 42 | 37 |
Shares Outstanding (Diluted) | 67 | 63 | 55 | 42 | 42 | 37 |
Shares Change | 5.91% | 14.72% | 30.79% | 0.92% | 11.89% | 236.49% |
EPS (Basic) | -0.97 | -1.18 | -1.58 | -2.34 | -2.62 | -2.73 |
EPS (Diluted) | -0.97 | -1.18 | -1.58 | -2.34 | -2.62 | -2.73 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -84.29 | -86.15 | -101.31 | -119.33 | 192.4 | -53.56 |
Free Cash Flow Per Share | -1.27 | -1.37 | -1.84 | -2.84 | 4.63 | -1.44 |
Gross Margin | -114.57% | -176.51% | - | -221.15% | - | - |
Operating Margin | -186.38% | -265.64% | -443.70% | -315.93% | -609.20% | -7637.15% |
Profit Margin | -175.78% | -240.33% | -383.24% | -288.17% | -566.27% | -7681.58% |
Free Cash Flow Margin | -229.43% | -278.72% | -448.24% | -349.38% | 1000.63% | -4060.88% |
EBITDA | -66.35 | -78.78 | -97.17 | -104.46 | -113.82 | -97.51 |
EBITDA Margin | -180.61% | -254.86% | - | - | - | - |
D&A For EBITDA | 2.12 | 3.33 | 3.12 | 3.45 | 3.32 | 3.23 |
EBIT | -68.48 | -82.11 | -100.29 | -107.91 | -117.14 | -100.73 |
EBIT Margin | -186.38% | -265.64% | - | - | - | - |